However, they have only exhibited minimal effects on histopathology in NAFLD.[50] Pioglitazone, a PPARγ selective agonist, has been confirmed effective in treating patients with NAFLD and type 2 diabetes. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.